Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension
Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension
The development of disease-targeted drugs for the treatment of pulmonary arterial
 hypertension (PAH) has significantly improved within the last years. Combining drug products
 with different mechanisms of action such as Endothelin-Receptor-Antagonists (ERAs) and
 Phosphodiesterase-Type-5-inhibitors (PDE-5-Inhibitors) has become increasingly important for
 the treatment of PAH. Recently, the results of the AMBITION study reported that an upfront
 combination treatment of ambrisentan and tadalafil immediately after diagnosis leads to a
 delayed disease progression. On the other hand, the sequential combination of bosentan and
 sildenafil did not show a similar positive clinical effect and this was attributed to a
 negative clinically relevant pharmacodynamic drug-drug interaction. Although, recent
 guidelines have extrapolated that initial upfront combination treatment follows a class
 effect in terms of efficacy and safety, there is an imperative need to support this notion
 with other combinations of ERAs and PDE-5-Inhibitors.
The primary objective of BOTA study is to compare the change in clinical and hemodynamic
 measures of PAH after the initiation of first line combination therapy with bosentan and
 tadalafil in adult patients with PAH. The safety and tolerability of first line combination
 therapy will also be evaluated.

 In patients with PAH initial upfront combination treatment with bosentan and tadalafil

 1. Improves

 -  Exercise capacity as expressed by distance walked in six minute walk test and WHO
 functional class

 -  Hemodynamics in terms of pulmonary vascular resistance (PVR), mean pulmonary artery
 pressure (mPAP) reduction and cardiac index (CI) elevation

 -  Quality of life

 -  NTproBNP serum levels

 -  Echocardiographic prognostic parameters such as right atrial area and presence of
 pericardial effusion.

 2. Is safe as assessed by

 -  Liver function markers such as serum SGOT and SGPT levels

 -  Hemoglobin levels
Inclusion Criteria:

 Male or females between 18 to 75 years of age at inclusion

 Diagnosis of PAH due to the following:

 -  Idiopathic Primary Pulmonary Arterial Hypertension (IPAH)

 -  Hereditary PAH

 -  PAH secondary to connective tissue disease

 -  PAH diagnosis confirmed by right heart catheterization performed within 3 months prior
 to study enrolment Subjects must weigh at least 40 kg at inclusion Subject must have a
 current diagnosis of being in World Health Organisation (WHO) Functional Class II or
 III.

 Treatment PAH naïve subjects PAH documented by

 -  mPAP ≥25mmHg,

 -  pulmonary capillary wedge pressure (PCWP) or

 -  left ventricular end-diastolic pressure (LVEDP) ≤15mmHg and

 -  PVR ≥3 Wood Units. Subject must walk a distance of ≥125m and ≤500m at the screening
 visit

 Exclusion Criteria:

 -  History of pulmonary embolism

 -  No prior treatment with PDE-5 inhibitors

 -  History of chronic lung disease / restrictive lung disease (eg, chronic obstructive
 pulmonary disease (COPD) or scleroderma) with impairment of lung function

 -  Current treatment with nitrates or nitric oxide

 -  Significant (ie, >2+) valvular disease other than tricuspid regurgitation or pulmonary
 regurgitation

 -  History of cardiac arrest, respiratory arrest, hemodynamic collapse, CPR, ventricular
 tachycardia, ventricular fibrillation, or uncontrolled atrial fibrillation